Abstract
BACKGROUND: Glucagon-like peptide-1 receptor agonists may have a role in modulation of cardiac fibrosis. Our study aimed to determine the effect of the glucagon-like peptide-1 receptor agonist liraglutide in obesity, hypertension and age-induced murine models of cardiac fibrosis and identify associated molecular mechanisms. METHODS: C57Bl/6J mice on a high-fat diet and C57Bl/6J mice on a normal chow diet treated with angiotensin II were used to induce obesity and hypertension-mediated cardiac fibrosis, respectively. C57Bl/6J mice 20 months old were used to study age-induced cardiac fibrosis. Liraglutide treatment of 30 microg/kg/day-300 microg/kg s.c. twice daily was administered for 4 weeks. RESULTS: Liraglutide treatment attenuated obesity, hypertension and age-induced increases in interstitial cardiac fibrosis and expression of inflammatory and oxidative stress markers. CONCLUSIONS: These observations identify a potential role for liraglutide in the prevention of cardiac fibrosis and identify molecular mechanisms associated with these effects.
Original language | English |
---|---|
Pages (from-to) | 56-68 |
Number of pages | 13 |
Journal | Diabetes & Vascular Disease Research |
Volume | 13 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2016 |
Keywords
- Glucagon-like peptide-1 receptor agonist
- cardiac fibrosis
- macrophage
- anti-inflammatory
- oxidative stress